Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, has completed a $30 million Series C financing led by Todd Pedersen, with continued participation from existing investors. Advancing HT-8184 Proceeds from the financing will be used to support the advancement of Halia’s lead asset, HT-6184, a selective and orally bioavailable first-in-class inhibitor of NLRP3/NEK7 inflammasome in Phase ...